Victory Capital Management Inc. cut its position in Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 43.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 104,019 shares of the biopharmaceutical company’s stock after selling 79,931 shares during the quarter. Victory Capital Management Inc. owned about 0.09% of Fate Therapeutics worth $341,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the company. RPO LLC acquired a new position in Fate Therapeutics during the fourth quarter worth approximately $46,000. Vestal Point Capital LP bought a new position in shares of Fate Therapeutics during the 4th quarter worth approximately $4,825,000. Superstring Capital Management LP acquired a new position in shares of Fate Therapeutics during the 4th quarter worth approximately $3,171,000. Pennant Investors LP bought a new stake in Fate Therapeutics in the 4th quarter valued at $546,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Fate Therapeutics during the 1st quarter valued at $432,000. 97.54% of the stock is currently owned by institutional investors and hedge funds.
Fate Therapeutics Trading Down 5.9 %
NASDAQ FATE opened at $3.64 on Tuesday. The company has a market cap of $414.35 million, a price-to-earnings ratio of -1.90 and a beta of 1.84. The company has a 50 day moving average of $4.04 and a 200-day moving average of $4.50. Fate Therapeutics, Inc. has a 1-year low of $1.63 and a 1-year high of $8.83.
Analyst Upgrades and Downgrades
FATE has been the topic of several research reports. Piper Sandler upgraded shares of Fate Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $4.00 to $6.00 in a report on Monday, June 17th. Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a research note on Wednesday, August 14th. Finally, HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Fate Therapeutics in a research report on Thursday, August 22nd. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $6.90.
View Our Latest Research Report on FATE
About Fate Therapeutics
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Featured Articles
- Five stocks we like better than Fate Therapeutics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- The Average 401k Balance by Age Explained
- How to Read Stock Charts for Beginners
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is the Nikkei 225 index?
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.